A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00109109
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purposes of this study are: * To determine the maximum tolerated dose (MTD) of SAHA administered every 12 hours for 14 consecutive days followed by 7 days of rest during the first two cycles (i.e., first 6 weeks) in patients with advanced multiple myeloma; * To assess the safety and overall response rate to SAHA in patients with advanced multiple myeloma.

Key Dates

Start date
Dec 1, 2003
Status verified
Nov 2019
Primary completion
Feb 14, 2006
Completion
Feb 14, 2006

Study Design

Enrollment
60 participants
Allocation
NON_RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

PHASE I: Maximum tolerated dose (MTD) of vorinostat in patients with advanced multiple myeloma.

Related Studies